• Sun. Apr 21st, 2024

Cartherics and TiCARos Join Forces to Enhance Effectiveness of NK Cell Therapies for Cancer Treatment

BySamantha Nguyen

Apr 3, 2024
Cartherics and TiCARos collaborate to lead advancement of CLIP-CAR technology

Cartherics, a leading developer of allogeneic NK cell therapies for cancer treatment, has joined forces with TiCARos, a company specializing in CAR-T cell products for solid and blood cancers. The collaboration aims to incorporate TiCARos’ CLIP-CAR constructs into Cartherics’ NK cells for assessing their function both in vitro and in vivo.

TiCARos’ CLIP-CAR technology is unique as it modifies the CAR structure to stabilize the immune synapse between immune cells and target tumor cells, resulting in improved efficacy in models. By combining this technology with Cartherics’ allogeneic NK cell platform, the two companies aim to enhance the effectiveness of cancer therapies.

Cartherics’ CEO, Professor Alan Trounson, believes that this collaboration has the potential to build a leading portfolio of therapeutic products for cancer treatment. The partnership aims to develop a CAR-NK product targeting tissue factor (TF) for triple negative breast cancer and other challenging cancers. Each company has nominated a specific tumor antigen to target with the CARs; Cartherics focuses on TF while TiCARos targets CD19.

The collaboration between these two innovative companies aims to accelerate pipeline programs and expand the use of TiCARos’ technology beyond autologous cell therapies. If the research collaboration yields positive results, Cartherics and TiCARos will negotiate a development and commercialization agreement for their CAR-NK therapeutic approach.

In summary, this collaboration between Cartherics and TiCARos is expected to lead to enhanced effectiveness of cancer therapies by utilizing innovative technologies such as CLIP-CAR constructs in combination with allogenic NK cells. The development of new CAR-NK products targeting specific tumor antigens could also lead to new treatments for challenging cancers like triple negative breast cancer.

By Samantha Nguyen

As a content writer at newsqwe.com, I am passionate about crafting engaging and informative articles that captivate our audience. With a background in journalism and a keen eye for detail, I strive to deliver content that is not only well-researched but also adds value to our readers' lives. From breaking news stories to in-depth features, I take pride in my ability to tell compelling stories that resonate with our diverse audience. When I'm not typing away at my keyboard, you can find me exploring new cafes, practicing yoga, or getting lost in a good book. I am thrilled to be a part of the newsqwe.com team and look forward to sharing my love for writing with all of our readers.

Leave a Reply